BackgroundImmuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC).ObjectiveThe ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients.Patients and MethodsPatients aged & GE; 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB).ResultsA total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p = 0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p < 0.001).ConclusionsOur study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations.

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study / Santoni, Matteo; Massari, Francesco; Myint, Zin W; Iacovelli, Roberto; Pichler, Martin; Basso, Umberto; Kopecky, Jindrich; Kucharz, Jakub; Buti, Sebastiano; Rizzo, Mimma; Galli, Luca; Büttner, Thomas; De Giorgi, Ugo; Kanesvaran, Ravindran; Fiala, Ondřej; Grande, Enrique; Zucali, Paolo Andrea; Fornarini, Giuseppe; Bourlon, Maria T; Scagliarini, Sarah; Molina-Cerrillo, Javier; Aurilio, Gaetano; Matrana, Marc R; Pichler, Renate; Cattrini, Carlo; Büchler, Tomas; Seront, Emmanuel; Calabrò, Fabio; Pinto, Alvaro; Berardi, Rossana; Zgura, Anca; Mammone, Giulia; Ansari, Jawaher; Atzori, Francesco; Chiari, Rita; Bamias, Aristotelis; Caffo, Orazio; Procopio, Giuseppe; Bassanelli, Maria; Merler, Sara; Messina, Carlo; Küronya, Zsófia; Mosca, Alessandra; Bhuva, Dipen; Vau, Nuno; Incorvaia, Lorena; Rebuzzi, Sara Elena; Roviello, Giandomenico; Zabalza, Ignacio Ortego; Rizzo, Alessandro; Mollica, Veronica; Sorgentoni, Giulia; Monteiro, Fernando Sabino M; Montironi, Rodolfo; Battelli, Nicola; Porta, Camillo. - In: TARGETED ONCOLOGY. - ISSN 1776-2596. - 18:4(2023), pp. 559-570. [10.1007/s11523-023-00978-2]

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

Buti, Sebastiano
Investigation
;
2023-01-01

Abstract

BackgroundImmuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC).ObjectiveThe ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients.Patients and MethodsPatients aged & GE; 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB).ResultsA total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p = 0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p < 0.001).ConclusionsOur study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations.
2023
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study / Santoni, Matteo; Massari, Francesco; Myint, Zin W; Iacovelli, Roberto; Pichler, Martin; Basso, Umberto; Kopecky, Jindrich; Kucharz, Jakub; Buti, Sebastiano; Rizzo, Mimma; Galli, Luca; Büttner, Thomas; De Giorgi, Ugo; Kanesvaran, Ravindran; Fiala, Ondřej; Grande, Enrique; Zucali, Paolo Andrea; Fornarini, Giuseppe; Bourlon, Maria T; Scagliarini, Sarah; Molina-Cerrillo, Javier; Aurilio, Gaetano; Matrana, Marc R; Pichler, Renate; Cattrini, Carlo; Büchler, Tomas; Seront, Emmanuel; Calabrò, Fabio; Pinto, Alvaro; Berardi, Rossana; Zgura, Anca; Mammone, Giulia; Ansari, Jawaher; Atzori, Francesco; Chiari, Rita; Bamias, Aristotelis; Caffo, Orazio; Procopio, Giuseppe; Bassanelli, Maria; Merler, Sara; Messina, Carlo; Küronya, Zsófia; Mosca, Alessandra; Bhuva, Dipen; Vau, Nuno; Incorvaia, Lorena; Rebuzzi, Sara Elena; Roviello, Giandomenico; Zabalza, Ignacio Ortego; Rizzo, Alessandro; Mollica, Veronica; Sorgentoni, Giulia; Monteiro, Fernando Sabino M; Montironi, Rodolfo; Battelli, Nicola; Porta, Camillo. - In: TARGETED ONCOLOGY. - ISSN 1776-2596. - 18:4(2023), pp. 559-570. [10.1007/s11523-023-00978-2]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2955532
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 6
social impact